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1. Introduction
Retinoblastoma is a highly malignant tumor of the eye that manifests most often in the first 3
years of life. Early detection is essential to preserve visual function, and decrease mortality
from retinoblastoma. Late diagnosis globally results in up to 70% mortality; where optimal
therapy is accessible, more than 95% of children are cured.
Telemedicine has many possible applications in ophthalmology, from community screening
to the provision of expertise in areas where it is otherwise not available. Broad-based appli‐
cations of telemedicine could greatly enhance screening efforts for potentially blinding
conditions such as diabetic retinopathy, macular degeneration, glaucoma, retinopathy of
prematurity as well as retinoblastoma. In this chapter we discuss specifically the application
of telemedicine in management of retinoblastoma. Telemedicine can help to bring subspecialty
expertise to small or rural communities, as well as to the developing world.
2. Retinoblastoma
2.1. Epidemiology
Retinoblastoma is the most common intraocular malignancy of childhood.[1] It represents
about 4% of all pediatric malignancies, and affects approximately 1 in in 20,000 live births each
year.[2] Most studies indicate that the incidence of retinoblastoma among various geographic
populations is relatively constant. There is a 95% survival rate in developed countries, however
the worldwide survival rate is closer to 50%. This is largely due to earlier detection in devel‐
oped countries, when the tumor is still confined to the globe. This is in contrast to underde‐
veloped areas where retinoblastomas are often diagnosed at an advanced stage, when they
have already invaded the orbit or brain.
© 2013 Moran O’ Keefe and ; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2.2. Genetics
Retinoblastoma arises from malignant transformation of primitive retinal cells before final
differentiation. It can be inherited as a familial tumor in which the affected child has a positive
family history of retinoblastoma or as a non-familial (sporadic tumor) in which the family
history is negative. Approximately 94% of newly diagnosed retinoblastoma cases are sporadic,
and 6% are familiar.
Retinoblastoma can be classified in 3 ways: familial or non-familial, heritable or non-heritable,
unilateral or bilateral, however the 3 classifications are interrelated [3] Bilateral and familial
retinoblastomas are caused by a germline tumor and are therefore heritable. Unilateral
sporadic retinoblastoma is usually non-heritable, however it is estimated that 10-15% of
children with unilateral sporadic retinoblastoma can have a germline mutation.
The retinoblastoma gene is located on the long arm of chromosome 13 (13q14). In order for
retinoblastoma to develop, both copies of the gene at the 13q14 locus must be affected. If either
the maternal or paternal copy of the gene that is inherited by an individual is defective, then
the individual is heterozygous for the mutant allele. Tumor formation requires both alleles to
be mutant or inactive- the concept of the “two-hit” hypothesis of Knudson. In familial cases,
all the retinal precursor cells contain the initial mutation, and a when a second hit occurs, the
cell undergoes malignant transformation. These children develop multifocal and bilateral
tumors, and are at higher risk of non-ocular secondary tumors such as pinealoblastomas and
osteosarcomas. In contrast, patients with unilateral sporadic retinoblastoma have normal
chromosome structure elsewhere in the body and are at no higher risk of secondary tumors.
In heritable retinoblastoma, the mutation is transmitted in 50%, but due to incomplete
penetrance only 40% of offspring will be affected. If a child has heritable retinoblastoma, the
risk to siblings is 2% if the parents are unaffected, and 40% if a parent is affected. In non-
heritable cases the risk in each sibling and offspring is about 1%.
Genetic testing using DNA analysis of the patient’s tumor can help to identify those with a
germline or heritable mutation. Heritable tumors account for approximately 40% of tumors
with the remainder being non-hereditary.
2.3. Presentation and clinical features
Presentation is usually within the first year of life if the tumor is bilateral or second year of life
if the tumor is unilateral. Clinical features vary according to time of presentation. Leukocoria
is the most common presenting feature (60%) and may be first noticed in family photographs.
(Figure 1.) Strabismus is the next most common form of presentation (20%); therefore dilated
fundal examination is mandatory in all cases of childhood strabismus. Retinoblastoma may
also present with chronic uveitis, orbital inflammation, secondary glaucoma, or orbital
invasion in advanced cases. Metastatic disease before the detection of ocular involvement is
rare.
The growth pattern of retinoblastoma can be endophytic, exophytic, and intraretinal. Exo‐
phytic tumors grow from the retina outwards into the subretinal space, whereas endophytic
tumors grow inward from the retina towards the vitreous cavity. Occasionally the retinoblas‐
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toma can have a diffuse infiltration pattern, which manifests as a relatively flat infiltration of
the retina without an obvious tumor mass.
Group 1: Very favorable for maintenance of sight
A. Solitary tumor, smaller than 4 disc diameters (DD), at or behind the equator.
B. Multiple tumors, none larger than 4 DD, all at or behind the equator.
Group 2: Favorable for maintenance of sight
A. Solitary tumor, 4 to 10 DD at or behind the equator
B. Multiple tumors, 4 to 10 DD behind the equator.
Group 3: Possible for maintenance of sight
A. Any lesion anterior to the equator.
B. Solitary tumor, larger than 10DD behind the equator.
Group 4: Unfavorable for maintenance of sight
A. Multiple tumors, some larger than 10 DD.
B. Any lesion extending anteriorly to the ora serrata.
Group 5: Very unfavorable for maintenance of sight
A. Massive tumors involving more than one half the retina.
B. Vitreous seeding.
The system was designed to predict outcome from treatment with external beam radiotherapy (EBRT), used interna‐
tionally as the primary eye salvage treatment until introduction of chemotherapy in the 1980s.
Table 1. Reese-Ellsworth Classification
Figure 1. Leukocoria in a child with Retinoblastoma
Telemedicine in Management of Retinoblastoma
http://dx.doi.org/10.5772/57019
29
Figure 2. Group V Tumor Left Eye on Presentation (December 2011) The eye was subsequently enucleated.
The International Classification for Intraocular Retinoblastoma is a newer staging system. It divides intraocular retinoblastomas
into 5 groups, labeled A-E, based on the chances that the eye can be saved using current treatment options.
Group A
Small tumors away from foveola and disc
•Tumors <3mm confined to retina
•Located at least 3mm from foveola and 1.5mm from optic disc
Group B
All other tumors confined to the retina.
•Subretinal fluid <3mm from base of tumor
Group C
Local subretinal fluid or vitreous seeding
•Subretinal fluid alone >3mm and <6mm from tumor
•Vitreous or subretinal seeding <3mm from tumor
Group D
Diffuse subretinal fluid or seeding
•Subretinal fluid >6mm from tumor
•Vitreous or subretinal seeding >3mm from the tumor
Group E
Presence of 1 or more of following poor prognostic features
•More than two-thirds of the globe filled with tumor
•Tumor in anterior segment or anterior to vitreous
•Tumor in/on ciliary body
•Iris neovascularization
•Neovascular glaucoma
•Opaque media from hemorrhage
Table 2. International Classification of Retinoblastoma
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Figure 3. Fellow eye of the same patient: Multiple Tumors in Right eye at time of presentation (December 2011)
2.4 Differential diagnosis
Approximately 50% of patients diagnosed with possible retinoblastoma prove to have
simulating conditions and not retinoblastoma. [4] Differential diagnoses include Persistent
Hyperplastic Primary Vitreous, Coats disease, and ROP. It is essential to establish the diagnosis
of retinoblastoma prior to commencing treatment.
2.5 Diagnosis
Diagnosis is established through a combination of history and physical examination, usually
requiring binocular indirect fundoscopy with scleral indentation. This is generally performed
under anesthesia to precisely determine the number and location of tumors. An experienced
examiner can establish the diagnosis based on the clinical appearance of the tumor. Ancillary
diagnostic studies can be helpful if the diagnosis is uncertain. Ultrasonography and computed
tomography can demonstrate the mass and detect presence of calcium. Magnetic resonance
imaging is of value for assessing the optic nerve, orbit, and brain and evaluating spread outside
the globe.
3. Management of retinoblastoma
The  primary  objective  in  management  of  retinoblastoma  is  survival  of  the  child,  and
secondly the preservation of the globe. After safety of the patient and the globe is establish‐
ed comes the focus on maintaining visual acuity. Treatment is tailored to each individual
case,  and there are several  options.  Intraocular retinoblastoma continues to be managed
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with a wide range of treatment modalities including cryotherapy, laser photocoagulation,
transpupillary  thermotherapy,  brachytherapy,  external  beam  radiation,  and  enucleation.
Newer  treatment  modalities  include  intra-vitreal  and  subconjunctival  chemotherapy  for
advanced tumors, and the recently described technique of ophthalmic artery catheteriza‐
tion with chemotherapy infusion. [5, 6, 7]
The approach to retinoblastoma management has changed significantly over the last 10 years,
with a move away from external beam radiation and increased use of focal treatment methods
and chemoreduction. It has been well demonstrated that patients with germline tumors are at
increased risk of developing secondary cancers if they receive external beam radiation. In
recent years, eyes with unilateral retinoblastoma are generally managed with enucleation if
the eye is classified as Reese-Ellsworth group V. For those eyes in group I-IV, chemoreduction
or focal treatment is used. In bilateral cases, chemoreduction is used in most cases unless there
is very asymmetric disease.
3.1. Chemoreduction
Chemoreduction  is  a  method  of  reducing  tumor  volume  to  allow  for  focal  therapeutic
measures such as cryotherapy or laser photocoagulation. This approach helps to preserve
vision and avoid external beam radiotherapy. Tumors may show dramatic response in the
first few months of treatment, however they will recur if treatment is not consolidated with
local  methods.  Choice  of  agents  as  well  as  number  and  frequency  of  cycles  varies  be‐
tween institutions. The main problem with chemoreduction is the recurrence of vitreous or
subretinal seeds, which may respond to initial chemoreduction, but later recur.
3.2. Periocular chemoreduction
Local  periocular chemotherapy can be administered in the subconjunctival  or  subtenons
space. For children with advanced retinoblastoma, systemic chemoreduction with a local
periocular boost of  subconjunctival  or subtenon chemotherapy can be used in advanced
tumors.  If  used  alone,  recurrence  is  inevitable,  therefore,  periocular  chemotherapy  is
combined  with  systemic  chemotherapy  for  best  results.  For  small  volume  intraocular
retinoblastomas,  focal  therapy may be potentially curative but can threaten vision if  the
tumor is adjacent to the macula or optic nerve. In these cases, periocular chemoreduction
can be effective whilst  avoiding systemic chemotherapy or  damaging vision using focal
therapies.
3.3. Intravitreal chemotherapy
The use of intravitreal chemotherapy was pioneered by Ericson and Rosengren, [8] and has
been studied extensively in animal models. It is widely used in Japan but has largely been
avoided  elsewhere  due  to  concerns  regarding  tumor  seeding.  A  recent  technique  has
described combining the intravitreal injection with a bleb of subconjunctival chemothera‐
py to avoid tumor seeding.[9]
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3.4. Intra-arterial chemotherapy
The concept of intra-arterial chemotherapy for retinoblastoma was introduced more than
50 years  ago,  when the alkylating agent  triethylene melanamine was used via puncture
sites in the carotid artery in the side of the eye to be treated.
Most  recently,  the  technique  of  supraselective  intraarterial  chemotherapy  appears  to
significantly improve the prognosis for eye preservation (70-80%) of group D eyes.  [10, 11]
Currently this treatment is employed in retinoblastoma patients as primary treatment for
unilateral  or  bilateral  retinoblastoma and as  secondary treatment  following failure  from
other treatments. This technique allows selective delivery of chemotherapy to the eye with
minimal systemic absorption. The dose delivered to the eye is 10 times that achieved with
systemic chemotherapy. This high dose of chemotherapy delivered to the eye accelerates
regression of tumor and seeds. The chemotherapy infusion has to be repeated every 3-4
weeks  for  up  to  3-6  injections  for  complete  regression  of  tumor.  Cannulation  of  the
ophthalmic  artery  is  difficult  in  children particularly  in  infants  less  than 6  months  and
requires  surgical  expertise  and  precision.  As  it  is  an  invasive  procedure  the  risk  of
neurological complications has to be considered though they are rare.
3.5. Focal therapy
Modalities of focal therapy include laser photocoagulation, cry therapy, thermotherapy, and
plaque radiotherapy.  These are mostly used for small  tumors,  in particular those which
have been already reduced by chemo reduction.
3.5.1. Laser photocoagulation
Laser photocoagulation is usually employed for small tumors posterior to the equator of
the  eye.It  tends  not  to  be  used  in  conjunction  with  chemo reduction  as  its  success  de‐
pends on vascular coagulation and tumor ischemia, which is the opposite case for chemo‐
reduction. It is performed using argon or diode laser, with two rows of photocoagulation
surrounding  the  tumor  base.  The  tumor  itelf  is  avoided  as  this  could  lead  to  vitreous
seeding. It is repeated at approximately 1-month intervals for 3 sessions.
3.5.2. Cryotherapy
Cryotherapy was first  introduced by Linkoff  in  1967.  It  causes  cell  death by destroying
circulation during the freeze, via damage to the vascular endothelium and decreased blood
flow. This is a useful treatment for equatorial and peripheral small retinoblastomas. The
tumor is  destroyed with one or two sessions of  triple freeze-therapy.  It  is  an important
method  of  tumor  consolidation  following  chemoreduction,  and  is  especially  useful  for
management of recurrent subretinal seeds near the ora serrate
3.5.3. Thermotherapy
Thermotherapy coupled with chemoreduction is  suited for tumors adjacent to the fovea
and optic  nerve where  radiation or  laser  would possibly  induce visual  loss.  It  involves
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heating  the  tumor  using  a  diode  infrared  laser  system,  and  is  usually  performed  in
conjunction with chemoreduction.
3.5.4. Plaque radiotherapy
This is a form of brachytherapy in which a radioactive implant is placed on the sclera over the
base of a retinoblastoma. An average of 2 to 4 days of treatment time is required to deliver the
total radiation dose to the tumor. It is useful for tumors less than 8mm thick and 16mm in base.
Plaque radiotherapy can be used as a primary or secondary treatment. In the majority of cases
it is used as a secondary treatment to salvage a glove after prior failed treatment. The visual
outcome varies with tumor size and location as well as side effects such as radiation retinop‐
athy and papillopathy. Overall following 1 application of plaque radiotherapy there is an
approximately 80% tumor control rate at 4 years.[13]
3.6. External beam radiotherapy
Retinoblastoma is generally a radiosensitive tumor. External bean radiotherapy is a method
of delivering whole eye irradiation to treat advanced retinoblastoma, particularly when there
is advanced vitreous seeding. Recurrence of retinoblastoma after external beam radiation is a
problem that can develop in the first 1 -4 years after treatment. Radiation damage to the retina,
optic nerve, and lens can be challenging to manage.
External beam radiation was once employed in a large percentage of patients but has fallen
out of favor, largely because external beam radiation has the potential to increase the risk of
the development of additional nonocular cancers in survivors of germline retinoblastoma. It
is estimated that the risk approximates 1% per year of life.[13] Patients who develop a second
cancer and then survive that cancer have an increased risk for the development of nonocular
tumors of approximately 2% per year from the time of the second tumor diagnosis. The average
latency period between subsequent tumor diagnoses becomes progressively less with each
additional cancer that develops. Children radiated during the first year of life are between 2-8
times as likely to develop second cancers as those radiated after the age of 1 year.
Nonetheless external beam radiation remains an excellent method of preserving vision in a
child with retinoblastoma, and certain clinical situation demand its use. Unlike focal therapies,
external beam radiation can provide an excellent opportunity for useful vision in a macula that
is not affected by tumor. It may be considered as a primary option in children with small tumors
located within the macula, or for multifocal tumors where focal therapies are ineffective.
External beam radiation also continues to be the salvage treatment of choice after focal
treatments have failed. For children with advanced extraoculaar or metastatic disease,
radiation can also play a role in palliation along with chemotherapy.
3.7. Enucleation
Enucleation continues to be a frequently used and important method for managing retino‐
blastoma If there is advanced disease with no hope for useful vision in the affected eye, or
there is concern regarding tumor invasion into the optic nerve, choroid or orbit, then enuclea‐
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tion is appropriate. Also best considered for enucleation, are children with secondary glauco‐
ma, pars plana seeding, or anterior chamber seeding, Over 99% of patients with unilateral
retinoblastoma without microscopic or macroscopic extraocular disease are cured by enuclea‐
tion. The technique of enuclation is to gently remove the eye intact without seeding any
malignant cells into the orbit.
4. Telemedicine in management of retinoblastoma
4.1. Telemedicine
Telemedicine can be defined as the delivery of healthcare and sharing of medical knowledge
over distance using telecommunication means. It is used to support health care between
participants who are separated from each other.[14] It has the potential to improve the
accessibility, quality, and cost of healthcare, and may also contribute to medical education and
research. The concept of telemedicine was introduced about 30 years ago through the use of
telephones and facsimile machines. However today, telemedicine has advanced, integrating
medical and network technology, comprising remote diagnosis, expert consultation, informa‐
tion service, online checkups, and remote communication.
Telemedicine can be broadly divided into two categories: synchronous telemedicine uses
telecommunications for real-time interactions between participants (i.e. Videoconferencing),
as compared to store-and-forward telemedicine which captures patient data for subsequent
interaction with a remote expert (i.e. Digital radiology)
4.2. Applications in ophthalmology
The potential benefits of an effective telemedicine system in ophthalmology are many.
Telemedicine has a variety of possible applications in ophthalmology, from community
screening to the provision of expertise in areas where it is otherwise not available. Broad-based
applications of telemedicine could greatly enhance screening efforts for potentially blinding
conditions such as diabetic retinopathy, macular degeneration, glaucoma, retinopathy of
prematurity and retinoblastoma to name but a few. Telemedicine can bring subspecialty
expertise to small or rural communities, as well as to the developing world.
Tele-medicine applications in ophthalmology comprise both clinical and educational process‐
es between the send and receive sites. These can include:
• screening of a disease;
• formulation of a diagnosis and clinical management plan;
• secondary advice and support in clinical management plan;
• peer supervision and support;
• professional development through group discussion, lectures, and tutorials
Telemedicine in Management of Retinoblastoma
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• research and administration activities.
Typical telemedicine application in retinoblastoma includes the transfer of basic patient
information, transfer of high resolution images such as fundal photographs, pathology images,
magnetic resonance imaging pictures.
The use of telemedicine in retinoblastoma is not only useful to the specialist managing the
condition, but is also of a source of confidence and comfort to parent and families of children
with retinoblastoma to know that multiple experts are involved in the care of their child, and
their child is receiving the best possible treatment.
4.3. Importance of imaging in management of retinoblastoma
The RetCam® wide-angle camera provides wide-field imaging of the retina and anterior
segment, including the anterior chamber angle. Some small retinoblastomas, and vitreous
seeds, may be better seen on RetCam® images than with indirect ophthalmoscopy. Sequential
images are useful to determine if the tumors are growing or regressing. The anterior segment
and anterior chamber angle can also be well visualized with the RetCam®. Fluorescein
angiography using the RetCam® can assess vascularity, residual tumor activity, and recur‐
rences within laser scars.
4.4. Images used in telemedicine for the management of retinoblastoma
 
Figure 4. B scan ultrasonography of right and left eye of same patient at time of presentation in December 2011
showing multifocal tumors in the right eye, and the left globe filled with large tumor
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4.4.1. Diagnosis
Telemedicine is invaluable when the diagnosis of retinoblastoma is in doubt. Diagnosis is
generally established by the classic appearance of the retinal tumors by an experienced
examiner. The sooner the diagnosis is established the sooner the appropriate treatment can be
implemented and the better the prognosis.
Figure 5. Right Fundus following chemoreduction February 2012
Figure 6. May 2012: Images of the right eye during treatment with chemoreduction and focal therapy with laser pho‐
tocoagulation
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In our experience in the Children’s University Hospital in Dublin, all new cases of retinoblas‐
toma are discussed using an internet consultation service where fundus images, clinical
history, and proposed treatment are reviewed with a leading expert in retinoblastoma in the
Hospital for Sick Kids in Toronto, Canada. The diagnosis is confirmed, and a treatment plan
is agreed upon. This ensures standards of retinoblastoma management are of the highest
Figure 7. June 2012: Image from examination under anesthesia following chemoreduction and focal laser consolida‐
tion
Figure 8. August 2012. Fundal image from right eye following chemoreduction and focal laser photocoagulation
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quality, and the most up-to-date treatments are employed. Selected cases may be further
discussed via videoconferencing and electronic mail.
4.5. Treatment planning
As discussed earlier there are multiple treatment modalities available to treat retinoblastoma.
Treatment plans tailored to specific cases can be formulated between experts in different
countries by sharing medical knowledge and experiences. Remote experts can closely monitor
the progress of patients by sharing fundus images and other clinical information. In difficult
cases, or cases requiring enucleation it is especially useful to have the second opinion of an
objective expert to ensure the best possible care is delivered.
4.6. Cost effectiveness
The relatively small numbers of retinoblastoma patients worldwide means that ophthalmol‐
ogists and oncologists in developing countries are unlikely to have the experience to treat
without expert advice. As this is a curable disease, efforts toward early diagnosis and treatment
are not only worthwhile, but cost effective. In countries with limited resources especially,
telemedicine provides invaluable support and advice. For example, a telemedicine programme
for retinoblastoma has been implemented in Jordan and has improved treatment and survival
for children in that country. The RetCam allows for real-time teleconferencing.
There are strong arguments for tackling long term conditions to improve quality of life, while
being mindful of the need to contain costs. In particular, there is considerable interest in the
potential of telemedicine to generate cost effectiveness gains and even to yield cost savings,
Figure 9. September 2012.Fundal image from right eye taken during examination under anesthesia showing multiple
treated areas and inactive tumor
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while maintaining or improving patient outcomes. Evidence on the cost-effectiveness of
telehealth is accumulating; systematic reviewers have judged it as promising for managing
respiratory and cardiac disease and diabetes. Although evidence of the effect of telemedicine
on retinoblastoma cost effectiveness remains scarce, it is promising.
4.7. Medico-legal aspects
4.7.1. Protocols for telemedicine
To avoid medico-legal pitfalls, comprehensive policies should be in place to ensure that
patients receive the maximum benefit.
The limits of a telemedicine should be clarified. It is important to identify and outline the
responsibilities of everyone in who is involved in telemedicine interactions to ensure seamless
patient management. The credentials and insurance coverage of all licensed practitioners
involved in telemedicine applications should be clear. Failure to verify the credentials of a
consulting specialist could lead to claims of negligent referral if there is an adverse outcome.
The accepted “standard of care” for telemedicine in the relevant area should be identified. The
process for assuring confidentiality of patient information should be outlined including:
security and retention protections for electronic communication; protocols for identifying
people at distant locations; confidentiality agreements for third-parties; compliance with
confidentiality, and patient informed consent.
It is necessary also to outline standards for image acquisition, resolution bandwidth, trans‐
mission, storage resolution, method and time, retrieval, and manipulation, and to have backup
procedures in place in case of equipment failure, weather interference, or other emergency.
5. Summary
Retinoblastoma is the most common intraocular cancer of childhood; it continues to be a
challenge both diagnostically and therapeutically. Telemedicine has a large role to play in the
diagnosis and management of this retinoblastoma. In our experience, telemedicine enables
invaluable expert collaboration to ensure the best outcomes for patients with retinoblastoma.
Telemedicine has many potential applications in retinoblastoma management, both in the
developing and developed world.
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